Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $3.3 million.

  • Centessa Pharmaceuticals' Change in Account Payables rose 9226.26% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 13633.51%. This contributed to the annual value of -$4.6 million for FY2024, which is 6844.23% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Change in Account Payables stood at $3.3 million for Q3 2025, which was up 9226.26% from $177000.0 recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Change in Account Payables peaked at $3.3 million during Q3 2025, and registered a low of -$4.2 million during Q1 2024.
  • In the last 4 years, Centessa Pharmaceuticals' Change in Account Payables had a median value of $143000.0 in 2024 and averaged $27066.7.
  • In the last 5 years, Centessa Pharmaceuticals' Change in Account Payables tumbled by 18551.28% in 2023 and then surged by 195542.17% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Change in Account Payables (Quarter) stood at $2.6 million in 2022, then tumbled by 77.43% to $586000.0 in 2023, then tumbled by 75.6% to $143000.0 in 2024, then skyrocketed by 2193.71% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $177000.0 for Q2 2025, and -$2.1 million during Q1 2025.